Navigation Links
A 'Knock-Out' Match: Kelly Ripa and Molly Sims Team Up to Fight Ovarian Cancer
Date:6/10/2008

Stars to Appear in Public Service Announcements for QVC Presents Super

Saturday Live Benefiting The Ovarian Cancer Research Foundation

WEST CHESTER, Pa., June 10 /PRNewswire/ -- Kelly Ripa and Molly Sims are packing a one-two punch in the fight against ovarian cancer as the stars of the new public service announcements to promote QVC(R) Presents Super Saturday Live to benefit The Ovarian Cancer Research Fund (OCRF).

Ripa and Sims are scheduled to appear in both the print and television public service announcements promoting QVC Presents Super Saturday Live on QVC Saturday, July 26 from 2 - 4 PM (ET), with all net proceeds benefiting OCRF.

The exclusive sale, which was previously only available to Hamptons' tastemakers and celebrities, will reach QVC's 93 million U.S. homes, allowing shoppers throughout the country to get designer styles at a fraction of the suggested retail price while supporting OCRF.

Both Ripa and Sims are longtime supporters of OCRF, participating in charitable events and fundraisers as well as supporting educational initiatives for the organization. Ripa, who has served as host for Super Saturday for the past four years, will once again host the event in the Hamptons. Currently in its 11th year, Super Saturday will be broadcast live for the second consecutive year on leading multimedia retailer QVC.

"I am excited to be hosting this wonderful event and for the opportunity to support an organization that is so near and dear to my heart," said Ripa. "And the best part? I get to spend the day shopping for a great cause -- what could be better than that?"

Also an active supporter of Super Saturday, Sims says that she is "ecstatic to be a part of the endless fight against ovarian cancer" and praises the OCRF for its endeavors. "It truly is an honor to work with OCRF and help raise awareness for such an outstanding cause," she said.

"We are thrilled to be working with such powerful and insp
'/>"/>

SOURCE QVC, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bacteria beware: MIT student invents knock-out punch for antibiotic resistance
2. Silica smart bombs deliver knock-out to bacteria
3. New knock-out gene model provides molecular clues to breast cancer
4. Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act
5. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
6. Have the Last Laugh on Allergies This Season: Actress Molly Shannon Teams with The Allergy Foundation to Talk About Allergies
7. Foods Co Continues Fight to Help End Hunger in America
8. Researchers ID Inflammation-Fighting Pathway in Fat Cells
9. Cantimer, Inc. Awarded $996,000 Contract from U.S. Government to Develop Portable, Real-Time and Non-Invasive Hydration Measurement and Monitoring System for Use by Firefighters
10. AIDS/LifeCycle Raises a Record $11.5 Million to Fight AIDS
11. Enzyme may hold key to improved targeting of cancer-fighting drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3Health News:VHI Releases Annual Industry Report - Highlights Hospital, Nursing Facility Efficiency 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 3Health News:MassMutual Recognized as One of America's Healthiest Companies 2Health News:MassMutual Recognized as One of America's Healthiest Companies 3Health News:New research identifies modifiable risk factors for heart disease 2Health News:New research identifies modifiable risk factors for heart disease 3Health News:New research identifies modifiable risk factors for heart disease 4Health News:New research identifies modifiable risk factors for heart disease 5Health News:New research identifies modifiable risk factors for heart disease 6
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Mesa Labs Increases Quarterly Dividend 61255 1Neogen to Ring NASDAQs Closing Bell 14815 1Neogen to Ring NASDAQs Closing Bell 14815 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 1Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 3